Business Wire

AZ-BLUE-YONDER

Share
Avon International Leverages Blue Yonder’s AI Capabilities To Support Its Global Demand Planning, Production and Omni-Channel Strategy

The cosmetics industry is experiencing continued growth as consumers worldwide increasingly prioritize self-care and wellness. However, this growth has also led to a more competitive landscape, and companies must make strategic choices to differentiate themselves and maintain success in this dynamic market. That is why Avon International chose Blue Yonder Platform with Cognitive Demand Planning, Enterprise Supply Planning and Control Tower solutions to create an end-to-end next generation supply chain and support the company’s strategy and vision.

Avon International is a global beauty company operating in over 40 countries across Europe and Asia Pacific. The brand Avon has been in operation for over 135 years and has a business model based on relationship selling. Millions of independent representatives offer personalised beauty advice to their customers through offline and online channels. The brand is also accessed through wholesalers, retail stores and marketplaces.

Avon International was seeking to optimize its manufacturing and distribution processes in both Europe and Asia Pacific by establishing a "Planning Hub" for centralized demand and supply planning. To streamline demand planning, respond more quickly to their dynamic market and enhance decision-making, Avon International selected Blue Yonder’s flexible SaaS supply chain solutions, based on advanced artificial intelligence (AI) and machine learning (ML) capabilities.

“Avon International is committed to transforming itself to meet the needs of its customers, Representatives and partners while staying true to its business model and values. To support this global transformation across all channels, Avon International recognized the need for a more integrated approach to demand planning. After a thorough selection process, Blue Yonder was chosen for its comprehensive solutions and innovative capabilities that met all of Avon International’s needs. With Blue Yonder’s supply chain solutions, powered by leading-edge AI and ML capabilities, Avon International will be empowered to meet the changing needs of its customers, representatives, and partners in a profitable and sustainable way,” said Maciej Kaniowski, COO, Avon International.

The need to reduce inventory across the company has made accurate forecasting and efficient demand planning a business imperative. Blue Yonder solutions’ key differentiators include not only the robustness, experience, and scalability of ML forecasting, but also the extensibility and explainability of causal factors, that for Avon include campaigns, price, promotions, catalogue position, and seasonality.

These factors train Blue Yonder’s ML models to predict future demand. Blue Yonder’s explainability and scenario composable services help planners understand causal contributions and run simulations based on changes like price or promotions, resulting in superior accuracy, greater explainability, and improved decision-making.

Once the Blue Yonder solutions are implemented, Avon International will be able to drive supply chain process simplification and achieve the following benefits:

  • Streamline operations with an integrated, end-to-end planning process for managing trends, demand, supply, inventory, and vendor collaboration.
  • Surpass forecast accuracy and achieve improved planner efficiency with the configuration of Avon’s causal factors.
  • Expand omni-channel capabilities and gain a competitive edge by forecasting and planning for all channels and offer types in one solution.
  • Improve service levels and optimize cash flow with a comprehensive forecasting and planning solution that supports a centralized planning hub.

Avon International’s manufacturing supply chain operations in Europe and Asia Pacific are managed by Avon Operations Polska (AOP) and Avon Distribution Polska (ADP), with the backbone of their activities located in Garwolin, Poland. AOP manages the largest and most technologically advanced Avon factory worldwide. Cosmetics manufactured here are distributed to approximately 40 countries on three continents.

"We are thrilled to be a part of Avon International’s supply chain digital transformation. It is an honor to work with a company that shares our same commitment to values such as inclusion, women empowerment, and equity. The Blue Yonder solutions will enable Avon International to adapt to changing market conditions and external dynamics, ensuring their supply chain remains agile, sustainable, and competitive," said Terry Turner, president, Manufacturing, Blue Yonder.

Additional Resources:

About Avon

At Avon, we believe a better world for women is a better world for all. We are the beauty brand for women embracing their power, inspiring their confidence and providing opportunities to realise their potential. Millions of independent sales Representatives across the world sell iconic Avon brands through their social networks and more than 20% of every sale helps to create better futures for women*. We stand for progress for women: we believe in listening to women’s needs, speaking out about issues that matter and creating positive change. Through Avon and the Avon Foundation, we have donated over $1.1 billion, with a focus on tackling gender violence and breast cancer. Avon is part of the Natura &Co Group.
*Learn more at www.avonworldwide.com.

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702770779/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye